▟ Vinebot intrinsic value, daily

← back

CVS CVS Health

healthcare · valued with opus medium conviction · deep-dived 2026-10-19

BUY
Intrinsic value$64.76
Price (at call)$92.36
Margin of safety -29.9%
vs market (rating basis) +11.4%

Scale franchise at trough margins; value depends on whether Aetna's recovery returns margins to about 3.8%.

The story

CVS is a vertically integrated health giant (Aetna insurance, Caremark PBM, retail pharmacy, Oak Street/Signify care delivery) with enormous scale but thin, cyclical margins. Margins collapsed as Medicare Advantage medical costs spiked and retail pharmacy eroded, and a repricing-driven Aetna recovery is now underway. It is a mature business: growth roughly tracks healthcare spending, and value depends on getting margins back toward historical norms rather than on expansion.

Revenue growth of about 5% fades to 2.5%, in line with nominal healthcare spending. Operating margin recovers from a depressed 2.1% to 3.8% over four years as MA repricing and PBM and retail restructuring take hold. That is below the 4.5%+ of the pre-2023 peak, reflecting regulatory and PBM pressure. The baseline of $5 per share is an artifact of carrying trough margins forward; at a normalized margin, value reconciles with a market price that already embeds a partial recovery.

Value drivers

Revenue growth (Y1)5.0%
Terminal growth2.5%
Forecast horizon7y
Target operating margin3.8%
Years to target margin4
Sales-to-capital3.00
Beta0.90
Failure probability2.0%
Cost of capital (WACC)8.8%
Terminal WACC9.1%

Valuation bridge

PV of explicit FCFF37.45B
PV of terminal value103.35B
Equity value82.83B
÷ shares → per share$64.76

Projected free cash flow to the firm

YrRevenueGrowthMarginNOPATReinvestFCFFPV
1 435.84B 5.0% 2.6% 9.01B 6.92B 2.09B 1.93B
2 455.82B 4.6% 3.0% 10.95B 6.66B 4.30B 3.63B
3 474.81B 4.2% 3.4% 13.00B 6.33B 6.67B 5.18B
4 492.61B 3.8% 3.8% 15.14B 5.94B 9.21B 6.57B
5 509.03B 3.3% 3.8% 15.65B 5.47B 10.18B 6.68B
6 523.88B 2.9% 3.8% 16.10B 4.95B 11.16B 6.73B
7 536.98B 2.5% 3.8% 16.51B 4.37B 12.14B 6.73B

Key risks

  • Medicare Advantage utilization and star-ratings or rate pressure keep Aetna's MLR elevated
  • PBM reform legislation and FTC actions compress Caremark spread and rebate economics
  • Continued retail pharmacy decline, reimbursement cuts, and heavy leverage (~$56B net debt) limit flexibility

Catalysts

  • Aetna margin recovery from MA repricing and benefit cuts showing up in quarterly MLR
  • Deleveraging plus store closures and cost programs lifting free cash flow and EPS guidance

History

DatePriceIntrinsicMoSRating
2026-10-19$92.36 $64.76 -29.9% BUY
2026-08-28$92.92 $9.94 -89.3% STRONG SELL
2026-07-08$104.33 $27.72 -73.4% SELL
2026-06-23$101.57 $26.91 -73.5% SELL